{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:57:00Z","timestamp":1794898620866,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by abnormal immune system activity, primarily affecting the working-age population. The study aimed to evaluate SLE\u2019s burden of disease from a societal perspective in the Kingdom of Saudi Arabia (KSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The burden of disease model was developed using Microsoft Excel\n                      <jats:sup>\u00ae<\/jats:sup>\n                      as the analytical tool for a one-year time frame. It was based on various inputs gathered through a literature review, input from key opinion leaders, and one-way sensitivity analysis, followed by local Delphi panel validation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall economic burden of SLE proper, lupus nephritis, and lupus central nervous system (CNS) for one year amounted to SAR 46,187,056, SAR 78,776,030, and SAR 19,822,905, respectively. This condition resulted in 263.6\u2009years lived with disability (YLD) and 251.1\u2009years of life lost (YLL), resulting in a total of 514.7 disability-adjusted life years (DALYs), valued at SAR 58,768,258 for SLE proper. For lupus nephritis, the burden is 542.96 DALYs (232.12 YLD and 310.85 YLL), amounting to SAR 61,995,057 and 129.67 DALY (10.55 YLD and 119.12 YLL) valued at SAR 14,805,541 for lupus CNS. Event management cost was the primary contributor to the economic burden, followed by high drug acquisition cost, which also significantly adds to overall healthcare expenses. The introduction of biologics to the treatment of SLE is expected to curb the monetary losses due to the humanistic burden of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To address the potential burden of SLE on the Saudi healthcare system, it is recommended to improve access to biologic therapies, enhance disease awareness, and implement targeted policy measures to support effective resource allocation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12962-025-00678-w","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:23:18Z","timestamp":1764051798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical, humanistic, and economic burden of systemic lupus erythematosus in the Kingdom of Saudi Arabia"],"prefix":"10.1186","volume":"23","author":[{"given":"Ahmed","family":"Al-jedai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajer","family":"Al-Mudaiheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayef Al","family":"Ghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysa","family":"Eshmawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-6938","authenticated-orcid":false,"given":"Ibrahim","family":"AlHomood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Dhopte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-5597","authenticated-orcid":false,"given":"Rita","family":"Ojeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"678_CR1","doi-asserted-by":"publisher","first-page":"102615","DOI":"10.1016\/j.jaut.2021.102615","volume":"119","author":"A Thanou","year":"2021","unstructured":"Thanou A, Jupe E, Purushothaman M, Niewold TB, Munroe ME. Clinical disease activity and flare in SLE: current concepts and novel biomarkers. J Autoimmun. 2021;119:102615.","journal-title":"J Autoimmun"},{"key":"678_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11926-021-00984-1","volume":"23","author":"A Weinstein","year":"2021","unstructured":"Weinstein A, Alexander RV, Zack DJ. A review of complement activation in SLE. Curr Rheumatol Rep. 2021;23:16.","journal-title":"Curr Rheumatol Rep"},{"key":"678_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11926-021-00985-0","volume":"23","author":"A Charras","year":"2021","unstructured":"Charras A, Smith E, Hedrich CM. Systemic lupus erythematosus in children and young people. Curr Rheumatol Rep. 2021;23:20.","journal-title":"Curr Rheumatol Rep"},{"key":"678_CR4","volume-title":"StatPearls","author":"AA Justiz Vaillant","year":"2024","unstructured":"Justiz Vaillant AA, Goyal A, Varacallo M. Systemic lupus erythematosus. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"678_CR5","first-page":"330","volume":"6","author":"M Cojocaru","year":"2011","unstructured":"Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011;6:330\u201336.","journal-title":"Maedica (bucur)"},{"key":"678_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.31138\/mjr.290723.los","volume":"34","author":"MA Bindroo","year":"2023","unstructured":"Bindroo MA, et al. Late onset systemic lupus erythematosus - clinical and autoantibody profile and its comparison with young onset systemic lupus erythematosus. Mediterr J Rheumatol. 2023;34:454\u201359.","journal-title":"Mediterr J Rheumatol"},{"issue":"2","key":"678_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/rheumatology\/kex412","volume":"57","author":"AM Jorge","year":"2018","unstructured":"Jorge AM, Lu N, Zhang Y, Rai SK, Choi HK. Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). Rheumatology (Oxford). 2018;57(2):337\u201344.","journal-title":"Rheumatol (oxford)"},{"issue":"30","key":"678_CR8","doi-asserted-by":"publisher","first-page":"e26704","DOI":"10.1097\/MD.0000000000026704","volume":"100","author":"IA Almaghlouth","year":"2021","unstructured":"Almaghlouth IA, Hassen LM, Alahmari HS, et al. National systemic lupus erythematosus prospective cohort in Saudi Arabia: a study protocol. Medicine (Baltimore). 2021;100(30):e26704.","journal-title":"Med (baltim)"},{"issue":"6","key":"678_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1177\/0961203316678677","volume":"26","author":"AM Al Dhanhani","year":"2017","unstructured":"Al Dhanhani AM, Agarwal M, Othman YS, Bakoush O. Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE. Lupus. 2017;26(6):664\u201369.","journal-title":"Lupus"},{"issue":"4","key":"678_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","volume":"20","author":"C Jo","year":"2014","unstructured":"Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327\u201337.","journal-title":"Clin Mol Hepatol"},{"key":"678_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/BOR.0000000000000480","volume":"30","author":"G Stojan","year":"2018","unstructured":"Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018;30:144\u201350.","journal-title":"Curr Opin Rheumatol"},{"key":"678_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1756-185X.14130","volume":"24","author":"NK Al-Adhoubi","year":"2021","unstructured":"Al-Adhoubi NK, et al. A multicenter longitudinal study of the prevalence and mortality rate of systemic lupus erythematosus patients in Oman: Oman lupus study. Int J Rheum Dis. 2021;24:847\u201354.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"678_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41927-024-00387-6","volume":"8","author":"M Schultze","year":"2024","unstructured":"Schultze M, Garal-Pantaler E, Pignot M, et al. Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany. BMC Rheumatol. 2024;8(1):18.","journal-title":"BMC Rheumatol"},{"issue":"6","key":"678_CR14","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/rheumatology\/kead427","volume":"63","author":"C Lao","year":"2024","unstructured":"Lao C, White D, Rabindranath K, et al. Mortality and causes of death in systemic lupus erythematosus in New Zealand: a population-based study. Rheumatology (Oxford). 2024;63(6):1560\u201367.","journal-title":"Rheumatol (oxford)"},{"issue":"9","key":"678_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515\u201332.","journal-title":"Nat Rev Rheumatol"},{"key":"678_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2147\/IJGM.S449068","volume":"17","author":"NA Alhammadi","year":"2024","unstructured":"Alhammadi NA, Alqahtani HS, Mahmood SE, et al. Pulmonary manifestations of systemic lupus erythematosus among adults in Aseer Region, Saudi Arabia. Int J Gen Med. 2024;17:1007\u201315.","journal-title":"Int J Gen Med"},{"issue":"4","key":"678_CR17","first-page":"e57842","volume":"16","author":"Y Alammari","year":"2024","unstructured":"Alammari Y, Albednah FA, Alharbi KA, et al. Cardiovascular morbidity in systemic lupus erythematosus: a single-center retrospective study. Cureus. 2024;16(4):e57842.","journal-title":"Cureus"},{"issue":"10","key":"678_CR18","first-page":"e18858","volume":"13","author":"N Alhassan","year":"2021","unstructured":"Alhassan N, Almetri T, Abualsoud S, et al. Causes of hospitalization for systemic lupus erythematosus in Saudi Arabia compared with the global setting: a retrospective single-center observational study. Cureus. 2021;13(10):e18858.","journal-title":"Cureus"},{"key":"678_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7861\/clinmedicine.17-1-78","volume":"17","author":"MF Shaikh","year":"2017","unstructured":"Shaikh MF, Jordan N, D\u2019Cruz DP. Systemic lupus erythematosus. Clin Med (Lond). 2017;17:78\u201383.","journal-title":"Clin Med (lond)"},{"issue":"sup1","key":"678_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/13696998.2024.2318996","volume":"27","author":"A Alansari","year":"2024","unstructured":"Alansari A, Hannawi S, Aldhaheri A, et al. The economic burden of systemic lupus erythematosus in United Arab Emirates. J Med Econ. 2024;27(sup1):35\u201345.","journal-title":"J Med Econ"},{"key":"678_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0961203315627202","volume":"25","author":"YH Lee","year":"2016","unstructured":"Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25:727\u201334.","journal-title":"Lupus"},{"key":"678_CR22","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1177\/0961203311415560","volume":"20","author":"H Al Durahim","year":"2011","unstructured":"Al Durahim H, Al Ghamdi G, Al Seraya A, Alkhiari R, Al Sayyari A. Predictors of mortality and end stage renal disease in Saudi patients with lupus nephritis. Lupus. 2011;20:1329\u201335.","journal-title":"Lupus"},{"key":"678_CR23","doi-asserted-by":"publisher","unstructured":"Arnaud L, Fabry-Vendrand C, Todea R, et al. Economic burden of systemic lupus erythematosus and lupus nephritis in France: a nationwide population-based study using the French medico-administrative (SNDS) claims database. Joint Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2024.105827. Published online 2024 Nov 30.","DOI":"10.1016\/j.jbspin.2024.105827"},{"key":"678_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/13696998.2024.2318996","volume":"27","author":"A Alansari","year":"2024","unstructured":"Alansari A, et al. The economic burden of systemic lupus erythematosus in United Arab Emirates. J Med Econ. 2024;27:35\u201345.","journal-title":"J Med Econ"},{"key":"678_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/acr.24510","volume":"74","author":"A Anandarajah","year":"2022","unstructured":"Anandarajah A, et al. Identification and characterization of a high-need, high-cost group among hospitalized patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2022;74:648\u201355.","journal-title":"Arthritis Care Res (hoboken)"},{"issue":"1","key":"678_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rdc.2009.12.006","volume":"36","author":"J Yazdany","year":"2010","unstructured":"Yazdany J, Yelin E. Health-related quality of life and employment among persons with systemic lupus erythematosus. Rheum Dis Clin N Am. 2010;36(1):15\u2013vii.","journal-title":"Rheum Dis Clin N Am"},{"key":"678_CR27","doi-asserted-by":"publisher","first-page":"e000640","DOI":"10.1136\/lupus-2021-000640","volume":"9","author":"S Grabich","year":"2022","unstructured":"Grabich S, Farrelly E, Ortmann R, Pollack M, Wu SS-J. Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the medical expenditure panel survey (MEPS) 2016\u20132018. Lupus Sci Med. 2022;9:e000640.","journal-title":"Lupus Sci Med"},{"key":"678_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40273-012-0007-4","volume":"31","author":"R Meacock","year":"2013","unstructured":"Meacock R, Dale N, Harrison MJ. The humanistic and economic burden of systemic lupus erythematosus: a systematic review. Pharmacoeconomics. 2013;31:49\u201361.","journal-title":"Pharmacoeconomics"},{"key":"678_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrrheum.2016.137","volume":"12","author":"EE Carter","year":"2016","unstructured":"Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12:605\u201320.","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"678_CR30","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/keac610","volume":"62","author":"MRW Barber","year":"2023","unstructured":"Barber MRW, Falasinnu T, Ramsey-Goldman R, Clarke AE. The global epidemiology of SLE: narrowing the knowledge gaps. Rheumatology (Oxford). 2023;62(Suppl 1):i4\u20139.","journal-title":"Rheumatol (oxford)"},{"issue":"1","key":"678_CR31","doi-asserted-by":"publisher","first-page":"e000907","DOI":"10.1136\/lupus-2023-000907","volume":"10","author":"B Neupane","year":"2023","unstructured":"Neupane B, Shukla P, Slim M, et al. Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. Lupus Sci Med. 2023;10(1):e000907.","journal-title":"Lupus Sci Med"},{"key":"678_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.17712\/nsj.2023.3.20220127","volume":"28","author":"YM Alammari","year":"2023","unstructured":"Cooper JT, Lloyd A, Sanchez JJG, et al. Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. Health Qual Life Outcomes. 2020, Sep, 21;18(1):310.","journal-title":"Neurosciences (riyadh)"},{"key":"678_CR33","doi-asserted-by":"crossref","unstructured":"Solli O, Stavem K, Kristiansen I. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8:18.","DOI":"10.1186\/1477-7525-8-18"},{"key":"678_CR34","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3899\/jrheum.100482","volume":"38","author":"E Aghdassi","year":"2011","unstructured":"Zen M, Salmaso L, Amidei CB, et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: data from a large population-based study. Eur J Intern Med. 2023;112.","journal-title":"J Rheumatol"},{"key":"678_CR35","first-page":"e30330","volume":"14","author":"MA Ameer","year":"2022","unstructured":"Hasan MA, et al. Anxiety and depression and associated risk factors among outpatients with systemic lupus erythematosus: Eastern Province, Saudi Arabia. Clin Pract. 2024;14:486\u201397.","journal-title":"Cureus"},{"key":"678_CR36","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/art.37795","volume":"65","author":"CH Feldman","year":"2013","unstructured":"Alammari YM, et al. An evaluation of neuropsychiatric manifestations in systemic lupus erythematosus patients in Saudi Arabia and their associated factors. Neurosciences (Riyadh). 2023;28:177\u201383.","journal-title":"Arthritis Rheum"},{"key":"678_CR37","doi-asserted-by":"crossref","unstructured":"Aghdassi E, et al. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol. 2011;38:658\u201366.","DOI":"10.3899\/jrheum.100482"},{"issue":"7","key":"678_CR38","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/acr.24546","volume":"74","author":"Z Touma","year":"2022","unstructured":"Ameer MA, et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022;14:e30330.","journal-title":"Arthritis Care Res (hoboken)"},{"issue":"10","key":"678_CR39","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1177\/0961203310373780","volume":"19","author":"YM Chiu","year":"2010","unstructured":"Feldman CH, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among us adults with Medicaid coverage, 2000\u20132004. Arthritis Rheum. 2013;65:753\u201363.","journal-title":"Lupus"},{"issue":"1","key":"678_CR40","doi-asserted-by":"publisher","first-page":"e000066","DOI":"10.1136\/lupus-2014-000066","volume":"2","author":"S Al Sawah","year":"2015","unstructured":"Kim H, et al. Cost-of-illness changes before and after the diagnosis of systemic lupus erythematosus: a nationwide, population-based observational study in Korea. Rheumatology (Oxford). 2023;kead664.","journal-title":"Lupus Sci Med"},{"issue":"1","key":"678_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1191\/0961203306lu2260oa","volume":"15","author":"GS Alarc\u00f3n","year":"2006","unstructured":"Touma Z, Hoskin B, Atkinson C, et al. Systemic lupus erythematosus symptom clusters and their association with patient-reported outcomes and treatment: analysis of real\u2013world data. Arthritis Care Res (Hoboken). 2022;74(7):1079\u20131088.","journal-title":"Lupus"},{"key":"678_CR42","doi-asserted-by":"crossref","unstructured":"Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus. 2010;19(10):1250\u20131255.","DOI":"10.1177\/0961203310373780"},{"issue":"1","key":"678_CR43","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12955-020-01559-x","volume":"18","author":"JT Cooper","year":"2020","unstructured":"Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus\u2014the hopkins lupus cohort. Lupus Sci Med. 2015;2(1):e000066.","journal-title":"Health Qual Life Outcomes"},{"key":"678_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7525-8-18","volume":"8","author":"O Solli","year":"2010","unstructured":"Alarc\u00f3n GS, Bastian HM, Beasley TM, et al. Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: contributions of admixture and socioeconomic status to renal involvement. Lupus. 2006;15(1):26\u201331.","journal-title":"Health Qual Life Outcomes"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00678-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00678-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00678-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:50:28Z","timestamp":1781617828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-025-00678-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["678"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00678-w","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}